Imara
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Imara (NASDAQ: IMRA) was a Boston biopharmaceutical company developing tovinontrine (IMR-687), a PDE9 inhibitor designed to boost fetal hemoglobin for sickle cell disease and beta thalassemia, plus IMR-261, an alternative hemoglobin-disorder approach. It had raised about $144.8 million.
02 / Imara FAILURE REASONS
Failure factors
Imara's April 5, 2022 company PR (via BioSpace/GlobeNewswire) and follow-on SEC Form 8-K state that Phase 2b interim analyses of tovinontrine (IMR-687) showed no significant VOC benefit in sickle cell disease and no meaningful benefit in beta-thalassemia, so Imara discontinued those trials and further development in those indications; the 8-K also records discontinuation of HFpEF/IMR-261 plans and an ~83% workforce reduction while evaluating strategic options.
Ardent Phase 2b interim analysis: no significant difference in median annualized VOC rate for high-dose tovinontrine vs placebo (ITT).
Forte Phase 2b interim analysis: no meaningful benefit in transfusion burden or most disease-related biomarkers in beta-thalassemia.
Company discontinued Ardent/Forte trials and further tovinontrine development in SCD and beta-thalassemia; 8-K also discontinued HFpEF and IMR-261 plans.
03 / EVENT HISTORY
Events in the structured record
- Phase 2b flops
On April 5, 2022, Imara announced that tovinontrine failed interim analyses in the Ardent (sickle cell) and Forte (beta thalassemia) Phase 2b trials, and discontinued both studies and the program.
- Layoffs and asset sale
Imara cut 83% of its workforce and sold the tovinontrine/PDE9 program to Cardurion for $34.75 million upfront plus $60 million in milestones.
- Merger with Enliven
Imara merged with Enliven Therapeutics, with Enliven's kinase-inhibitor pipeline and $165 million private financing continuing under the Enliven name.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
A failed primary endpoint is a company-killer for single-asset biotechs — plan portfolio diversification before Phase 2 readouts.
- 02
Changing the endpoint mid-study didn't save tovinontrine; don't bet the company on statistical reshuffling.
- 03
When trials fail, cutting 83% of staff quickly and selling the program for milestones preserves some shareholder value.
- 04
Have merger partners mapped before the readout — Imara moved to Enliven rather than liquidate.